This cross-sectional observational case-control study aims to investigate symptoms of sluggish cognitive tempo (SCT), also known as cognitive disengagement syndrome (CDS), in adults diagnosed with Functional Neurological Symptom Disorder/Conversion Disorder (FNSD/CD). The study compares SCT/CDS symptoms between patients with FNSD/CD and healthy controls and evaluates their relationship with clinical variables. It is hypothesized that individuals diagnosed with FNSD/CD will exhibit higher levels of SCT/CDS symptoms compared to healthy controls.
Eligibility
Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
Accepted
* Inclusion Criteria for the Functional Neurological Symptom Disorder (FNSD) Group:
1. Meeting the diagnostic criteria for FNSD/CD according to DSM-5-TR at the time of admission
2. Being between 18-65 years of age
3. Absence of additional psychiatric disorders
4. Absence of alcohol/substance use disorder
5. Absence of neurological disorders affecting cognition
6. Being in remission with FNSD/CD
7. Completing sociodemographic data fully
8. Willingness to complete the forms and scales.
9. Willingness to participate in the study
* Exclusion Criteria for the FNSD Group:
1. Being under 18 or over 65 years of age
2. Not meeting the diagnostic criteria for FNSD/CD according to DSM-5-TR
3. Active alcohol/substance use
4. Having neurological diseases affecting cognitive functions (such as Alzheimer's disease, delirium, Parkinson's disease)
5. Not being willing to participate in the study
6. Incomplete sociodemographic data
7. Not being willing to complete forms and scales.
* Inclusion Criteria for the Healthy Control (HC) Group
1. Being between 18-65 years of age
2. Not having any psychiatric disorder
3. Not having an alcohol/substance use disorder
4. Not having a neurological disorder affecting cognition
5. Completing sociodemographic data in full
6. Being willing to complete the forms and scales.
7. Being willing to participate in the study
* Exclusion Criteria for the HC Group:
1. Being under 18 or over 65 years of age
2. Having a psychiatric disorder
3. Active alcohol/substance use
4. Having neurological diseases affecting cognitive functions (such as Alzheimer's disease, delirium, Parkinson's disease)
5. Not being willing to participate in the study
6. Incomplete sociodemographic data
7. Not being willing to complete forms and scales.
Primary outcome measure(s)
Barkley's Adult Sluggish Cognitive Tempo Ratings Scale -Turkish Version (SCT) — At hospital admission (baseline) Adult Sluggish Cognitive Tempo Ratings Scale (SCT) was developed by choosing the symptom sets used in prior studies of SCT in children and adolescents. It is a self-report scale and included the following nine items: "1. Prone to daydreaming when I should be concen trating"; "2. I have trouble staying alert or awake in boring situations"; "3. I am easily confused"; "4. I am easily bored"; "5. My mind is spacey or in a fog"; "6. I am lethargic, more tired than others"; "7. I am underactive or have less energy than others"; "8. I am a slow- moving"; "9. I don't seem to process information as quickly or as accurately as others.".Barkley suggested using the number of SCT symptoms answered often or very often as a total score and 5 or higher total score as a cutoff point for having elevated SCT.
Somatoform Dissociation Questionnaire (SDQ-20) — At hospital admission (baseline) The Somatoform Dissociation Questionnaire is a self-assessment scale which is administered to psychiatric patients, individuals with traumatic experiences, and non-clinical populations for screening purposes. The self-administered scale contains 20 questions, each answered with a scale of 1 to 5 options. Studies in Turkey have reported that individuals with a total score of 40 or higher have a high probability of having a dissociative disorder.
Trial sites (2)
Facility
City
Region
Status
Elazığ Mental Health and Diseases Hospital Psychiatry Clinic
Elâzığ
Elâzığ
Not Yet Recruiting
Elazığ Mental Health and Diseases Hospital
Elâzığ
Elâzığ
Recruiting
More Elazığ Mental Health and Diseases Hospital trials in Turkey
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.